NEO-201

NEO-201 is a humanized antibody targeting CEACAM6/CD66c with antitumor activity that binds to tumor-associated variants of carcinoembryonic antigen-associated cellular adhesion molecule (CEACAM)-5 and CEACAM-6, and can be used in the study of breast cancer.

Methods: Tumor target cells were labeled with Calcein AM, treated with 10 μg/mL NEO-201, and co-incubated with NK-92 cells at a target-to-killer cell ratio of 1.56:1 to 12.5:1 for 16 hours; the number of live cells was detected using Celigo imaging, and the NK cell-specific killing rate was calculated.
Results: NEO-201 significantly enhanced the killing activity of NK-92 cells against CEACAM5⁺/NEO-201⁺ tumor cells. The killing effect was positively correlated with the expression level of CEACAM5⁺/NEO-201⁺ and was not affected by the expression level of CEACAM6 in tumor cells. [1]

Methods: Ovarian carcinoma in situ models (intra-ovarian injection of OV90) and peritoneal metastasis models were established. NEO-201 (250 μg/mouse) was administered via intraperitoneal injection on days 1, 4, and 8. Tumor volume was monitored by ultrasound, and mouse survival was recorded.
Results: NEO-201 prolonged the survival of tumor-bearing mice.

Human

Monoclonal

Unconjugated